PANTHERx® Rare Partnering with X4 Pharmaceuticals Inc. for the Distribution of XOLREMDI™ (mavorixafor), the First FDA-Approved Therapy Indicated for Use in Patients with WHIM Syndrome
April 29, 2024 PITTSBURGH – PANTHERx® Rare, a leader in rare disease product patient access and support services in the United...
Read More
KEEP & PANTHERx® Rare Forge Innovative Partnership to Advance the Specialty Therapy Experience in the Home
April 25, 2024 PITTSBURGH – An exciting advancement for the specialty pharmacy industry, KEEP announced a strategic partnership...
Read More
PANTHERx® Rare Continues Explosive Growth with Expansions of Pharmacy, HQ and Distribution Locations
April 25, 2024 PITTSBURGH – PANTHERx® Rare, the leader in rare disease pharmacy, patient access, and support services in the United...
Read More
PANTHERx® Rare Selected by Edenbridge Pharmaceuticals as Specialty Pharmacy for Yargesa® (miglustat 100 mg capsules)
April 01, 2024 PITTSBURGH – PANTHERx® Rare, a leader in rare disease product patient access and support services in the United...
Read More
PANTHERx® Rare Selected by Chiesi Global Rare Diseases for the Distribution of Filsuvez® (birch triterpenes) topical gel
February 07, 2024 PANTHERx® Rare, a leader in rare disease product patient access and support services in the United States,...
Read More
PANTHERx® Rare Selected by Chiesi Global Rare Diseases for the Distribution of Filsuvez® (birch triterpenes) topical gel
PANTHERx® Rare, a leader in rare disease product patient access and support services in the United States, is pleased to...
Read More
